trimethoprim has been researched along with Tuberculosis in 8 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to determine the susceptibility of clinical isolates of multidrug-resistant (MDR) and non-MDR Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and trimethoprim/sulfamethoxazole over a 12 year period in Taiwan." | 7.78 | Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. ( Chen, YS; Huang, TS; Kunin, CM; Lee, SS; Syu, W; Yan, BS, 2012) |
| "This study was designed to determine the susceptibility of clinical isolates of multidrug-resistant (MDR) and non-MDR Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and trimethoprim/sulfamethoxazole over a 12 year period in Taiwan." | 3.78 | Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. ( Chen, YS; Huang, TS; Kunin, CM; Lee, SS; Syu, W; Yan, BS, 2012) |
| "Twelve lipophilic 2,4-diamino-5-methyl-5-deazapteridine derivatives and trimethoprim were evaluated for activity against Mycobacterium tuberculosis and Mycobacterium avium in vitro." | 3.70 | Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. ( Barrow, EW; Barrow, WW; Piper, JR; Reynolds, RC; Suling, WJ; Wilson, LN, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Muzanyi, G | 1 |
| Peace, A | 1 |
| Wamuntu, B | 1 |
| Joseph, A | 1 |
| Nassali, J | 1 |
| Kashyap, G | 1 |
| Ameta, G | 1 |
| Ameta, C | 1 |
| Ameta, R | 1 |
| Punjabi, PB | 1 |
| Raju, A | 1 |
| Kulkarni, S | 1 |
| Ray, MK | 1 |
| Rajan, MG | 1 |
| Degani, MS | 1 |
| Huang, TS | 1 |
| Kunin, CM | 1 |
| Yan, BS | 1 |
| Chen, YS | 1 |
| Lee, SS | 1 |
| Syu, W | 1 |
| McConville, JH | 1 |
| Suling, WJ | 1 |
| Reynolds, RC | 1 |
| Barrow, EW | 1 |
| Wilson, LN | 1 |
| Piper, JR | 1 |
| Barrow, WW | 1 |
| Gelzer, J | 1 |
| Loustalot, P | 1 |
| Ludwig, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis[NCT01832987] | Phase 2 | 12 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for trimethoprim and Tuberculosis
| Article | Year |
|---|---|
The threat of persistent bacteria and fungi contamination in tuberculosis sputum cultures.
Topics: Amphotericin B; Anti-Bacterial Agents; Azlocillin; Bacteria; Bacteriological Techniques; Fungi; Huma | 2021 |
Synthesis and characterization of polyaniline-drug conjugates as effective antituberculosis agents.
Topics: Aniline Compounds; Antitubercular Agents; Dose-Response Relationship, Drug; Gram-Negative Bacteria; | 2019 |
E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Enzyme I | 2015 |
Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan.
Topics: Antitubercular Agents; Drug Interactions; Humans; Microbial Sensitivity Tests; Mycobacterium tubercu | 2012 |
Whither the roles of rifater and rifamate?
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Trimethoprim; T | 1996 |
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
Topics: Animals; Cell Survival; Chlorocebus aethiops; Folic Acid Antagonists; Humans; Microbial Sensitivity | 1998 |
Letter: Rifampicin: for tuberculosis only?
Topics: Animals; Bacterial Infections; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination | 1976 |
[Epididymitis].
Topics: Adult; Diagnosis, Differential; Drug Combinations; Epididymitis; Gonorrhea; Hernia; Humans; Infant, | 1977 |